[go: up one dir, main page]

BR9813998A - Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos - Google Patents

Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos

Info

Publication number
BR9813998A
BR9813998A BR9813998-3A BR9813998A BR9813998A BR 9813998 A BR9813998 A BR 9813998A BR 9813998 A BR9813998 A BR 9813998A BR 9813998 A BR9813998 A BR 9813998A
Authority
BR
Brazil
Prior art keywords
group
substituted
effective ingredients
pyridazine derivatives
medicinal products
Prior art date
Application number
BR9813998-3A
Other languages
English (en)
Inventor
Masao Ohkuchi
Yoshinori Kyotani
Hiromichi Shigyo
Tomoyuki Koshi
Takahiro Kitamura
Tadaaki Ohgiya
Takayuki Matsuda
Yukiyoshi Yamazaki
Natsuyo Kumai
Kyoko Kotaki
Hideo Yoshizaki
Yuriko Habata
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP31813397A external-priority patent/JP3999861B2/ja
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR9813998A publication Critical patent/BR9813998A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"NOVOS DERIVADOS DE PIRIDAZINA E PRODUTOS MEDICINAIS CONTENDO OS MESMOS COMO INGREDIENTES EFETIVOS"<D>. A presente invenção está relacionada a derivados de piridazina representados pela fórmula (1): Onde R1 representa um grupo aril (substituído, R2 representa um grupo fenil substituído na posição 4 por um grupo alcoxil inferior ou um grupo alquiltio inferior, R3 representa um grupo alcoxil inferior, um grupo alquil inferior halogenado, um grupo cicloalquil inferior, um grupo aril (substituído), um grupo ariloxi (substituído), um resíduo de anel heterocíclico contendo nitrogênio (substituído), um grupo aminocarbonil (substituído) ou um grupo alquilcarbonil inferior, A representa uma união simples, um grupo alquileno inferior ou um grupo alquenileno inferior, X representa O ou S, e a linha tracejada indica que a união carbono-carbono entre a posição 4- e a posição 5- é uma união simples ou dupla, ou sais do mesmo; e também remédios contendo os mesmos como ingredientes efetivos. Esses compostos têm excelente atividade inibidora contra a produção de interleukin-1ß e são úteis como preventivos e terapêuticos para enfermidades do sistema imunológico, enfermidades inflamatórias, enfermidades isquêmicas e similares.
BR9813998-3A 1997-11-19 1998-11-09 Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos BR9813998A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31813297 1997-11-19
JP31813397A JP3999861B2 (ja) 1997-11-19 1997-11-19 新規ピリダジン誘導体及びこれを有効成分とする医薬
PCT/JP1998/005023 WO1999025697A1 (fr) 1997-11-19 1998-11-09 Nouveaux derives de pyridazine et medicaments contenant ces composes comme principe actif

Publications (1)

Publication Number Publication Date
BR9813998A true BR9813998A (pt) 2000-09-26

Family

ID=26569260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813998-3A BR9813998A (pt) 1997-11-19 1998-11-09 Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos

Country Status (21)

Country Link
US (11) US6348468B1 (pt)
EP (2) EP1043317B1 (pt)
KR (1) KR100626605B1 (pt)
CN (1) CN1142148C (pt)
AT (1) ATE428700T1 (pt)
AU (1) AU738595B2 (pt)
BR (1) BR9813998A (pt)
CA (1) CA2307111C (pt)
DE (1) DE69840755D1 (pt)
DK (1) DK1043317T3 (pt)
ES (1) ES2324126T3 (pt)
HK (1) HK1032969A1 (pt)
HU (1) HUP0100059A3 (pt)
ID (1) ID24166A (pt)
MX (1) MXPA00004955A (pt)
NO (1) NO316021B1 (pt)
NZ (1) NZ504045A (pt)
PT (1) PT1043317E (pt)
RU (1) RU2209813C2 (pt)
TW (1) TW502025B (pt)
WO (1) WO1999025697A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504045A (en) * 1997-11-19 2001-06-29 Kowa Co Pyridazine derivatives with inhibitory action against interleukin-1-beta production
TW587079B (en) 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
ES2162731B1 (es) * 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
PE20011333A1 (es) * 2000-03-16 2002-01-16 Almirall Prodesfarma Ag Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
BR0212848A (pt) * 2001-09-26 2004-08-17 Kowa Co Derivados fenilpiridazina hidrossolúveis e medicamentos contendo os mesmos
MY128945A (en) * 2002-04-16 2007-03-30 Kowa Co Solid dispersion composition
US7074959B2 (en) * 2002-08-01 2006-07-11 New Mexico Highlands University Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces
CA2512280A1 (en) * 2003-03-07 2004-09-16 Kowa Co., Ltd. Benzofuran derivative
CA2518227A1 (en) * 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
JP4579825B2 (ja) * 2003-04-29 2010-11-10 興和株式会社 溶出性に優れた超難水溶性薬物含有組成物及びその製造法
EP1650195A4 (en) * 2003-07-30 2008-09-17 Kowa Co METHOD FOR INHIBITING OSTEOPONTIN PRODUCTION
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP1797882A4 (en) * 2004-09-29 2009-11-18 Kowa Co PREVENTIVE AND / OR THERAPEUTIC MEDICAMENT FOR RHEUMATOID ARTHRITIS
JPWO2006104172A1 (ja) * 2005-03-29 2008-09-11 興和株式会社 関節リウマチの予防及び／又は治療薬
KR20080038339A (ko) * 2005-08-31 2008-05-06 코와 가부시키가이샤 관절 류머티즘의 예방 및/또는 치료법
WO2007044796A2 (en) * 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
CN101296707A (zh) * 2005-10-28 2008-10-29 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
US20090203701A1 (en) * 2006-06-29 2009-08-13 Kowa Co., Ltd Prophylactic and/or therapeutic agent for rheumatoid arthritis
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
EP2099770B1 (en) 2006-12-21 2015-06-10 Sloan-Kettering Institute for Cancer Research Pyridazinones and furan-containing compounds
JPWO2008093495A1 (ja) 2007-01-29 2010-05-20 興和株式会社 多発性硬化症治療剤
US20100120732A1 (en) * 2007-03-09 2010-05-13 Kowa Co., Ltd. Agent for prevention and/or treatment of systemic lupus erythematosus
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007041115A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN102603676B (zh) * 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂
BR112018071216A2 (pt) 2016-04-15 2019-02-05 Abbvie Inc inibidores de bromodomínios
EP3532467A1 (en) * 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. Pyridazine derivatives, compositions and methods for modulating cftr
CN115087639A (zh) 2020-02-14 2022-09-20 Fmc公司 用作杀真菌剂的取代的5,6-二苯基-3(2h)-哒嗪酮
TW202222163A (zh) * 2020-08-14 2022-06-16 瑞士商先正達農作物保護公司 化學方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206496A1 (es) 1972-07-03 1976-07-30 Riker Laboratories Inc Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas
JPS58501432A (ja) * 1981-09-11 1983-08-25 エスディ−エス・バイオテック・コ−ポレ−ション 抗炎症，鎮痛性４−ピリジルピリダジン（２ｈ）−３−オン類
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd ５−（１ｈ−イミダゾール−１−イル）−３（２ｈ）−ピリダジノン誘導体
FI91062C (fi) 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
US5380718A (en) * 1990-05-15 1995-01-10 E. I. Du Pont De Nemours And Company Arthropodicidal fused tetrahydropyridazines
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH08311032A (ja) * 1995-05-18 1996-11-26 Eisai Co Ltd α，β−不飽和ケトン誘導体
CA2228050A1 (en) 1995-08-10 1997-02-20 Harold G. Selnick 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
WO1998041511A1 (en) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
ES2260846T3 (es) 1997-08-22 2006-11-01 Abbott Laboratories Inhibidores para la biosintesis de la prostaglandina h2 sintasa.
BR9812127A (pt) 1997-08-22 2000-07-18 Abbott Lab Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
NZ504045A (en) * 1997-11-19 2001-06-29 Kowa Co Pyridazine derivatives with inhibitory action against interleukin-1-beta production
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
PL198503B1 (pl) 1998-10-27 2008-06-30 Abbott Lab Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same

Also Published As

Publication number Publication date
CN1142148C (zh) 2004-03-17
AU9762698A (en) 1999-06-07
CA2307111A1 (en) 1999-05-27
KR100626605B1 (ko) 2006-09-22
CA2307111C (en) 2009-06-30
US20050065155A1 (en) 2005-03-24
EP1043317A4 (en) 2003-03-05
CN1279672A (zh) 2001-01-10
KR20010031880A (ko) 2001-04-16
NO316021B1 (no) 2003-12-01
US20090270399A1 (en) 2009-10-29
US20090069332A1 (en) 2009-03-12
DE69840755D1 (de) 2009-05-28
HUP0100059A3 (en) 2002-08-28
ID24166A (id) 2000-07-13
US20050267113A1 (en) 2005-12-01
US20070208025A1 (en) 2007-09-06
EP1043317B1 (en) 2009-04-15
PT1043317E (pt) 2009-05-11
NO20002169D0 (no) 2000-04-27
EP2017266A1 (en) 2009-01-21
US20060160804A1 (en) 2006-07-20
US20020123496A1 (en) 2002-09-05
US20040147516A1 (en) 2004-07-29
NO20002169L (no) 2000-05-18
US20080119474A1 (en) 2008-05-22
DK1043317T3 (da) 2009-07-06
HK1032969A1 (en) 2001-08-10
WO1999025697A1 (fr) 1999-05-27
US6348468B1 (en) 2002-02-19
NZ504045A (en) 2001-06-29
TW502025B (en) 2002-09-11
RU2209813C2 (ru) 2003-08-10
MXPA00004955A (es) 2002-10-17
AU738595B2 (en) 2001-09-20
ATE428700T1 (de) 2009-05-15
US20070049595A1 (en) 2007-03-01
EP1043317A1 (en) 2000-10-11
ES2324126T3 (es) 2009-07-30
HUP0100059A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
BR9813998A (pt) Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
ATE233250T1 (de) Saccharinderivate als proteolytische enzyminhibitoren
ATE231496T1 (de) Saccharinderivate als proteolytische enzyminhibitoren
FI950309A (fi) Proliiniamidijohdannaisia
TNSN05160A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
BRPI0509364B8 (pt) derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados
HUP0101461A2 (hu) Új piridazinszármazékok és az azokat hatóanyagként tartalmazó gyógyszerkészítmények
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
NO324219B1 (no) Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
BR0309558A (pt) Derivados de quinazolina e medicamentos
DE3561814D1 (en) Substituted bis-(4-aminophenyl)-sulphones, their preparation and their use as medicines
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
DE3584608D1 (de) Amidabkoemmlinge.
HUP0101224A2 (hu) Neuraminidáz inhibitor hatású pirrolidinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
ZA891783B (en) Peptides with pharmaceutical activity
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
DK412388D0 (da) Leukotrienantagonister, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse som laegemidler
ZA929974B (en) Pharmaceutical composition for inhibiting the infection with AIDS virus
BR9908948A (pt) Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DE INT.CL: C07D 237/04, C07D 237/14, C07D 237/18, C07D 401/04, C07D 401/14, A61K 31/50, A61K 31/501

Ipc: C07D 237/04 (2008.01), C07D 237/14 (2008.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15V Prolongation of time limit allowed

Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 56 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time